AI is reshaping the global liquid biopsy market, particularly in cancer applications, by improving biomarker detection, ctDNA analysis, and early cancer diagnosis. Its use is expanding across precision oncology, disease monitoring, clinical decision-making, and workflow optimization, while also influencing the liquid biopsy value chain, industry adoption, and investment priorities.
The report includes:
- Impact analysis of artificial intelligence (AI) on the global liquid biopsy market, with a focus on cancer applications
- Case studies for successful integration of AI and machine learning in biomarker detection, circulating tumor DNA (ctDNA) analysis, early cancer diagnosis and disease monitoring
- Highlights of AI adoption trends across major geographical regions, as well as disruptions caused by AI across key oncology, diagnostics and biotechnology industry verticals
- AI’s role in precision oncology, test development, clinical decision-making and workflow optimization
- Review of AI impact on the various stages of the global liquid biopsy value chain and supply chain analysis
- Competitive landscape featuring key strategic initiatives, market spendings and an investment outlook
Table of Contents
Chapter 1 Key Use Cases for AI Adoption in Liquid Biopsy with Emphasis on Cancer- Overview
- Key Use Cases/Case Studies
- Case 1: Next-Generation Sequencing (NGS)
- Case 2: Polymerase Chain Reaction (PCR)
- Case 3: Other Technologies
- Adoption Trends by Region
- Adoption Trends in North America
- Adoption Trends in Europe
- Adoption Trends in Asia-Pacific
- Adoption Trends in the Rest of the World
- Impact of AI on Key Industry Verticals
- Therapy Monitoring
- Recurrence Monitoring
- Therapy Guidance
- Early Cancer Screening
- Impact of AI on Various Stages of the Supply Chain
- Biomarker Discovery and Assay Development
- Sample Processing and Data Generation
- Data Analysis and Clinical Interpretation
- Clinical Application and Commercial Deployment
- Overview
- Market Spending and Forecasting Analysis
- Key Spending by Technologies for Liquid Biopsy with Emphasis on Cancer on AI
- Venture Capital Investment in AI for Liquid Biopsy with Emphasis on Cancer
- Notable Venture Capital Investments
- Abbreviations Used in the Report
Table 1: Key Initiatives by Companies on AI, 2025-2026
Table 2: Key Spending by Companies on AI-based Liquid Biopsy, 2023-2026
Table 3: Abbreviations Used in This Report
List of Figures
Figure 1: Impact of AI on Value Chain
